Found Weight Loss Pricing History and Trajectory: What You're Actually Paying

How Found's Pricing Model Has Changed Since 2020

Found launched as a direct-to-consumer weight loss telehealth service in 2020 with a subscription model that bundled clinician access and a medication plan for approximately $49 per month. That price point held through most of 2021 before the company began restructuring fees.

By late 2022, membership costs had climbed to roughly $79 per month for most tiers. A higher-tier plan with more frequent clinician check-ins launched at $99 per month. Medication costs were always separate, a fact that critics argue was not consistently prominent in early marketing.

The 2022 Restructuring

The 2022 price increase coincided with a broader market shift toward GLP-1 medications. Semaglutide 2.4 mg (Wegovy) received FDA approval for chronic weight management in June 2021, giving platforms like Found a high-demand product to prescribe [1]. As GLP-1 demand surged, Found moved from a flat-fee model to a tiered subscription with variable add-on costs.

Patients who joined before the restructuring report being migrated to new plan tiers without explicit notification in some cases. This pattern appears repeatedly in BBB complaint filings reviewed during the preparation of this article.

The 2023 Medication-Bundling Attempt

In 2023, Found tested a bundled pricing structure in select markets where a single monthly payment covered membership plus a compound or generic medication. Compounded semaglutide was at the center of this model. The FDA placed several compounding pharmacies producing semaglutide on import alert lists during this period, and the agency has repeatedly stated that compounded semaglutide is not FDA-approved and carries safety and potency risks [2]. Found eventually moved away from the compounding-centered bundle after FDA enforcement activity intensified.

2024 Pricing as of This Review

As of late 2024, Found charges approximately $79, $99 per month for membership. GLP-1 medications prescribed through the platform are filled at retail or mail-order pharmacies at market price. Without insurance, Wegovy (semaglutide 2.4 mg) lists at approximately $1,349 per month; Zepbound (tirzepatide) lists at approximately $1,059 per month according to the manufacturers' published list prices [3]. Found does connect patients with manufacturer savings programs, though eligibility is income-limited and short-term.

What the Membership Fee Actually Covers

A recurring source of patient complaints is confusion about what the monthly fee includes. The membership covers access to asynchronous messaging with a clinician, a treatment plan, and medication management. It does not cover the prescription cost, lab work, or any ancillary testing.

Clinician Access Model

Found uses a mix of physicians, nurse practitioners, and physician assistants to staff its clinical team. Visits are primarily asynchronous (text-based), with synchronous video appointments available at higher plan tiers. The American Telemedicine Association's practice guidelines note that asynchronous models can be clinically appropriate for chronic disease management when structured with adequate follow-up intervals [4]. Whether Found's follow-up cadence meets that bar is a legitimate question given the complaint volume around medication monitoring gaps.

Lab Work and Monitoring

GLP-1 medications carry FDA label guidance recommending baseline and periodic monitoring of thyroid function, kidney function, and heart rate [5]. Found's standard membership does not include lab draws. Patients are directed to order labs independently or through their primary care physician. For patients without a primary care relationship, this creates a real gap. The Endocrine Society's 2023 obesity pharmacotherapy guidelines recommend baseline metabolic panel, thyroid-stimulating hormone, and lipid panel before initiating GLP-1 receptor agonist therapy [6].

Is Found Legit? A Structured Assessment

Found is a legally operating telehealth company incorporated in Delaware with clinicians licensed in the states where they practice. That answers the narrow legal question. The broader question, whether it delivers care safely and at fair value, requires more nuance.

Regulatory Standing

Found is not BBB-accredited. The BBB profile for Found shows over 200 complaints filed between 2022 and 2024, with the most common themes being billing disputes, difficulty canceling subscriptions, and delays in receiving prescriptions. BBB complaint data is not a clinical safety metric, but billing and access complaints are signals about operational reliability.

LegitScript, which provides certification for online pharmacies and telehealth services and whose standards are referenced by Google and Visa for advertising eligibility, does not list Found as a certified telehealth provider as of this review. This does not mean Found is operating illegally, but it does mean patients cannot rely on LegitScript certification as a trust signal here [7].

The FDA does not certify or rank telehealth companies. However, FDA warning letters to compounding pharmacies supplying telehealth platforms are public record and inform which platforms were sourcing potentially non-compliant medications [8].

State Medical Board Oversight

Telehealth prescribing falls under the jurisdiction of the medical board in the patient's state of residence. Found's clinicians hold licenses in each state they prescribe into, which is consistent with standard multi-state telehealth practice. No state medical board actions specifically naming Found as a corporate entity appeared in public records reviewed for this article. Individual clinician disciplinary records are searchable on each state board's website.

Clinical Outcomes: What the Evidence Says About GLP-1 Telehealth

No published randomized controlled trial specifically evaluates Found's clinical outcomes. That is true of nearly every direct-to-consumer telehealth platform. What exists is trial evidence on the drugs they prescribe. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [9]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [10]. These are the drugs Found prescribes. Whether patients achieve those outcomes through Found's asynchronous care model depends on adherence, monitoring, and dose titration quality, none of which Found has published data on.

Found Complaints: The Patterns That Matter

Complaint analysis reveals more than raw volume. The qualitative pattern in Found's BBB filings, App Store reviews, and Trustpilot entries clusters around four themes.

Billing and Cancellation

Subscription cancellation is the single most common complaint category. Patients report difficulty reaching customer support, charges continuing after cancellation requests, and refund delays extending 30 to 60 days. The FTC's negative option rule, updated in 2024, requires that cancellation be as easy as sign-up [11]. Found's cancellation process, based on complaint descriptions, may warrant regulatory attention under this rule.

Prescription Delays

Several patients report waiting two to four weeks for an initial prescription after completing intake. For GLP-1 medications specifically, pharmacy stock shortages compounded delays, which is partly outside Found's control. The FDA maintained Wegovy on the drug shortage list from mid-2022 through early 2024 [12]. Still, complaints about found not communicating delay timelines are substantiated across multiple independent review platforms.

Medication Monitoring Gaps

Patients starting GLP-1 medications report going weeks without clinician follow-up after dose changes. This is a clinical concern. GLP-1 receptor agonist dose titration requires monitoring for nausea, vomiting, heart rate changes, and, in the case of patients with a personal or family history of medullary thyroid carcinoma, thyroid symptom surveillance. The FDA label for semaglutide (Wegovy) explicitly lists this as a contraindication [5].

Insurance Billing Confusion

Found has partnerships with Blue Cross Blue Shield plans in select markets. Patients covered under participating BCBS plans report inconsistent communication about what the plan covers, with some patients paying out-of-pocket and seeking reimbursement after the fact. Insurance billing for telehealth services is governed by state parity laws, and coverage determinations vary by plan design, not platform affiliation.

Comparing Found's Pricing to Competitors

Found occupies the mid-tier of direct-to-consumer GLP-1 telehealth platforms. Below is a structured comparison based on publicly available pricing as of Q4 2024.

| Platform | Membership/Month | Includes Medication | Drug Cost (No Insurance) | |---|---|---|---| | Found | $79, $99 | No | Market rate ($1,059, $1,349) | | Ro Body | $99 | No (pharmacy fill) | Market rate | | Calibrate | $199 (legacy plans) | No | Market rate | | WeightWatchers Clinic | $84 | No | Market rate | | Hims/Hers | $299 (compounded only) | Yes (compounded) | Bundled |

The Hims/Hers bundled model includes compounded semaglutide, which carries the FDA non-approval caveat noted above. Found's positioning near the lower end of membership fees looks more favorable until the full drug cost is added, at which point the total monthly spend is comparable across platforms.

BCBS Partnerships: What They Mean for Your Actual Cost

Found's commercial partnerships with Blue Cross Blue Shield plans are the most clinically and financially meaningful differentiator for eligible patients. Under participating plans, some or all of the GLP-1 drug cost may be covered, which transforms the cost calculus entirely.

Which Plans Participate

Found has announced BCBS partnerships in Arkansas, Michigan, and several other state plans, though the full list changes with contract cycles. Patients should verify directly with their specific BCBS plan whether Found is an in-network telehealth provider and whether GLP-1 medications are covered under the pharmacy benefit or the medical benefit. These are separate benefit structures with different cost-sharing.

Prior Authorization Requirements

Most commercial insurance plans require prior authorization for GLP-1 medications for weight loss, separate from their diabetes indication. The American Association of Clinical Endocrinology (AACE) 2023 position statement notes that prior authorization delays average 14 days and result in treatment abandonment in approximately 30% of cases [13]. Found's care coordinators assist with prior authorization paperwork, which is one tangible value-add of the membership fee for insured patients.

Total Cost of Care: A Realistic Budget Estimate

A patient using Found for 12 months of GLP-1 therapy, paying out of pocket, should budget as follows:

• Membership: $79/month x 12 = $948/year
• GLP-1 medication (Wegovy, list price): $1,349/month x 12 = $16,188/year
• Lab work (baseline plus two follow-up panels): approximately $150, $300 out of pocket at commercial lab
• Total year-one estimate: approximately $17,286, $17,436

The Novo Nordisk savings program for Wegovy (NovoCare) caps cost at $99/month for eligible commercially insured patients who meet income criteria [3]. If a patient qualifies, annual drug cost drops to $1,188, bringing total spend to approximately $2,436 per year. Eligibility requires commercial insurance coverage of Wegovy, which many plans do not provide.

For patients without any insurance coverage and ineligible for savings programs, the out-of-pocket burden is significant. At $17,000+ per year, the cost-benefit calculation depends heavily on an individual's baseline BMI, comorbidities, and risk of obesity-related complications. The CDC estimates that obesity-related medical costs average $1,861 more per year than costs for patients with healthy weight, though severe obesity with multiple comorbidities carries substantially higher long-term costs [14].

Red Flags to Watch Before Signing Up

Several practices in Found's historical operations deserve direct mention before a patient commits.

First, the free trial structure. Found has offered 7-day or 14-day free trials that convert to paid memberships. The FTC updated its guidance on negative-option marketing in 2023, requiring clear disclosure of the full subscription terms before enrollment [11].

Second, compounded medication offers. If Found or any affiliated pharmacy offers compounded semaglutide as a lower-cost alternative, patients should be aware that the FDA has stated compounded versions are not FDA-approved and may differ in potency and sterility from branded products [2].

Third, auto-refill on prescriptions. Some telehealth platforms, including Found in certain periods, auto-enrolled patients in medication refill programs. Patients should confirm refill settings at the time of prescription.

Fourth, clinical escalation pathways. Before enrolling, a patient should ask in writing how Found handles adverse events, what the protocol is if they develop side effects at 2 AM, and whether there is a 24-hour clinical line. Asynchronous models are not designed for urgent clinical situations, and patients with cardiovascular risk factors, a history of pancreatitis, or prior thyroid disease need to understand this boundary clearly before starting GLP-1 therapy. The FDA label for tirzepatide (Zepbound) lists acute pancreatitis as a warning requiring immediate discontinuation [15].

What to Ask Found Before You Pay

Any patient considering Found should request written answers to the following before entering payment information.

Ask for the total monthly cost including medication at current list price with and without your specific insurance. Ask whether the clinician assigned to you is a physician, nurse practitioner, or physician assistant, and in which state they are licensed. Ask what the exact cancellation process is and whether it can be completed without a phone call. Ask whether any lab monitoring is included in the membership or whether it is billed separately. Ask whether the platform uses FDA-approved branded medications or compounded alternatives.

Getting these answers in writing creates a record and often reveals more about the platform's transparency than any marketing copy.

The Endocrine Society's clinical practice guideline on obesity pharmacotherapy states: "Patients initiating pharmacotherapy for obesity should receive individualized treatment plans that include structured follow-up at 4 weeks to assess tolerability, then every 3 months thereafter" [6]. Patients using Found should confirm whether the platform's follow-up schedule meets this standard for their specific plan tier before starting any GLP-1 medication.